Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Jun;98(6):945-52.
doi: 10.3324/haematol.2012.081877. Epub 2013 Jan 24.

The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial

David I Marks  1 , Anthony V Moorman, Lucy Chilton, Elisabeth Paietta, Amir Enshaie, Gordon DeWald, Christine J Harrison, Adele K Fielding, Letizia Foroni, Anthony H Goldstone, Mark R Litzow, Selina M Luger, Andrew K McMillan, Janis Racevskis, Jacob M Rowe, Martin S Tallman, Peter Wiernik, Hillard M Lazarus
Affiliations
Randomized Controlled Trial

The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial

David I Marks et al. Haematologica. 2013 Jun.

Abstract

The biology and outcome of adult t(4;11)(q21;q23)/MLL-AFF1 acute lymphoblastic leukemia are poorly understood. We describe the outcome and delineate prognostic factors and optimal post-remission therapy in 85 consecutive patients (median age 38 years) treated uniformly in the prospective trial UKALLXII/ECOG2993. The immunophenotype of this leukemia was pro-B (CD10(NEG)). Immaturity was further suggested by high expression of the stem-cell antigens, CD133 and CD135, although CD34 expression was significantly lower than in t(4;11)-negative patients. Complete remission was achieved in 77 (93%) patients but only 35% survived 5 years (95% CI: 25-45%); the relapse rate was 45% (95% CI: 33-58%). Thirty-one patients underwent allogeneic transplantation in first remission (15 sibling donors and 16 unrelated donors): with 5-year survival rates of 56% and 67% respectively, only 2/31 patients relapsed. This compares with a 24% survival rate and 59% relapse rate in 46 patients who received post-remission chemotherapy. A major determinant of outcome was age with 71% of patients aged <25 years surviving. Younger patients had lower relapse rates (19%) but most received allografts in first complete remission. In conclusion, multivariate analysis did not demonstrate an advantage of allografting over chemotherapy but only five younger patients received chemotherapy. Prospective trials are required to determine whether poor outcomes in older patients can be improved by reduced-intensity conditioning allografts. NCT00002514 www.clinicaltrials.gov.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Overall survival of 85 adult patients with t(4;11)-positive acute lymphoblastic leukemia (ALL) treated in the UKALLXII/ECOG2993 study.
Figure 2.
Figure 2.
Patient flow chart. CRI: first complete remission.
Figure 3.
Figure 3.
(A) Relapse rate and survival of 77 adult patients with t(4;11)-positive acute lymphoblastic leukemia (ALL) treated in the UKALLXII/ECOG2993 study by treatment received in first remission. The 15 patients with unrelated donors include one transplanted from a mismatched related donor. (B) Relapse rate and survival of 85 adult patients with t(4;11)-positive acute lymphoblastic leukemia (ALL) treated in the UKALLXII/ECOG2993 study by age.
See this image and copyright information in PMC

References

    1. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111 (4):1827–33 - PubMed
    1. Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, et al. Induction therapy for adults with acute lymphoblastic leukaemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG 2993. Blood. 2005;106(12):3760–7 - PubMed
    1. Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, et al. Karyotype is an independent prognostic factor in acute lymphoblastic leukaemia: analysis of cytogenetic data from patients treated on the MRC UKALL XII/ECOG 2993 trial. Blood. 2007;109(8): 3189–97 - PubMed
    1. Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood. 2009;114(25): 5136–45 - PMC - PubMed
    1. Moorman AV. The clinical relevance of chromosomal and genomic abnormalities in B cell precursor acute lymphoblastic leukaemia. Blood Rev. 2012;26(3):123–35 - PubMed

Publication types

MeSH terms

Substances

Associated data